

**By** Senator Artiles

40-01109-17

20171618

1                   A bill to be entitled  
2       An act relating to controlled substances; amending s.  
3       893.03, F.S.; adding CBD (Cannabidiol) to the Schedule  
4       I list of controlled substances; providing an  
5       effective date.

6

7       Be It Enacted by the Legislature of the State of Florida:

8

9                   Section 1. Paragraph (c) of subsection (1) of section  
10      893.03, Florida Statutes, is amended to read:

11      893.03 Standards and schedules.—The substances enumerated  
12     in this section are controlled by this chapter. The controlled  
13     substances listed or to be listed in Schedules I, II, III, IV,  
14     and V are included by whatever official, common, usual,  
15     chemical, trade name, or class designated. The provisions of  
16     this section shall not be construed to include within any of the  
17     schedules contained in this section any excluded drugs listed  
18     within the purview of 21 C.F.R. s. 1308.22, styled "Excluded  
19     Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical  
20     Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted  
21     Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt  
22     Anabolic Steroid Products."

23      (1) SCHEDULE I.—A substance in Schedule I has a high  
24     potential for abuse and has no currently accepted medical use in  
25     treatment in the United States and in its use under medical  
26     supervision does not meet accepted safety standards. The  
27     following substances are controlled in Schedule I:

28      (c) Unless specifically excepted or unless listed in  
29     another schedule, any material, compound, mixture, or

40-01109-17

20171618

30 preparation that contains any quantity of the following  
31 hallucinogenic substances or that contains any of their salts,  
32 isomers, including optical, positional, or geometric isomers,  
33 homologues, nitrogen-heterocyclic analogs, esters, ethers, and  
34 salts of isomers, homologues, nitrogen-heterocyclic analogs,  
35 esters, or ethers, if the existence of such salts, isomers, and  
36 salts of isomers is possible within the specific chemical  
37 designation or class description:

- 38 1. Alpha-Ethyltryptamine.
- 39 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2-  
40 oxazoline).
- 41 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
- 42 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
- 43 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 44 6. Bufotenine.
- 45 7. Cannabis.
- 46 8. Cathinone.
- 47 9. DET (Diethyltryptamine).
- 48 10. 2,5-Dimethoxyamphetamine.
- 49 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
- 50 12. DMT (Dimethyltryptamine).
- 51 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog  
52 of phencyclidine).
- 53 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
- 54 15. N-Ethylamphetamine.
- 55 16. Fenethylline.
- 56 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
- 57 18. Ibogaine.
- 58 19. LSD (Lysergic acid diethylamide).

40-01109-17

20171618

- 59        20. Mescaline.
- 60        21. Methcathinone.
- 61        22. 5-Methoxy-3,4-methylenedioxyamphetamine.
- 62        23. PMA (4-Methoxyamphetamine).
- 63        24. PMMA (4-Methoxymethamphetamine).
- 64        25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
- 65        26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
- 66        27. MDA (3,4-Methylenedioxyamphetamine).
- 67        28. JB-336 (N-Methyl-3-piperidyl benzilate).
- 68        29. N,N-Dimethylamphetamine.
- 69        30. Parahexyl.
- 70        31. Peyote.
- 71        32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine analog of phencyclidine).
- 72        33. Psilocybin.
- 73        34. Psilocyn.
- 74        35. *Salvia divinorum*, except for any drug product approved by the United States Food and Drug Administration which contains *Salvia divinorum* or its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, if the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.
- 75        36. Salvinorin A, except for any drug product approved by the United States Food and Drug Administration which contains Salvinorin A or its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, if the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.
- 76        37. Xylazine.

40-01109-17

20171618

- 88        38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)  
89        (Thiophene analog of phencyclidine).  
90        39. 3,4,5-Trimethoxyamphetamine.  
91        40. Methylone (3,4-Methylenedioxymethcathinone).  
92        41. MDPV (3,4-Methylenedioxypyrovalerone).  
93        42. Methylmethcathinone.  
94        43. Methoxymethcathinone.  
95        44. Fluoromethcathinone.  
96        45. Methylethcathinone.  
97        46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-  
98        yl)phenol) and its dimethyloctyl (C8) homologue.  
99        47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-  
100        methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].  
101        48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).  
102        49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).  
103        50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-  
104        naphthoyl)indole).  
105        51. BZP (Benzylpiperazine).  
106        52. Fluorophenylpiperazine.  
107        53. Methylphenylpiperazine.  
108        54. Chlorophenylpiperazine.  
109        55. Methoxyphenylpiperazine.  
110        56. DBZP (1,4-Dibenzylpiperazine).  
111        57. TFMPP (Trifluoromethylphenylpiperazine).  
112        58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-  
113        Methylenedioxy-N-methylbutanamine).  
114        59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).  
115        60. 5-Hydroxy-N-methyltryptamine.  
116        61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).

40-01109-17

20171618

- 117        62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).  
118        63. Methyltryptamine.  
119        64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).  
120        65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).  
121        66. Tyramine (4-Hydroxyphenethylamine).  
122        67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).  
123        68. DiPT (N,N-Diisopropyltryptamine).  
124        69. DPT (N,N-Dipropyltryptamine).  
125        70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).  
126        71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).  
127        72. DOI (4-Iodo-2,5-dimethoxyamphetamine).  
128        73. DOC (4-Chloro-2,5-dimethoxyamphetamine).  
129        74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).  
130        75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).  
131        76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).  
132        77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).  
133        78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).  
134        79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).  
135        80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).  
136        81. Butylone (3,4-Methylenedioxy-alpha-  
137        methylaminobutyrophenone).  
138        82. Ethcathinone.  
139        83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).  
140        84. Naphyrone (Naphthylpyrovalerone).  
141        85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).  
142        86. 3,4-Methylenedioxy-N,N-diethylcathinone.  
143        87. 3,4-Methylenedioxy-propiophenone.  
144        88. 3,4-Methylenedioxy-alpha-bromopropiophenone.  
145        89. 3,4-Methylenedioxy-propiophenone-2-oxime.

40-01109-17

20171618

- 146        90. 3,4-Methylenedioxy-N-acetyl cathinone.
- 147        91. 3,4-Methylenedioxy-N-acetyl methcathinone.
- 148        92. 3,4-Methylenedioxy-N-acetyl ethcathinone.
- 149        93. Bromomethcathinone.
- 150        94. Buphedrone (alpha-Methylamino-butyrophenone).
- 151        95. Eutylone (3,4-Methylenedioxy-alpha-
- 152        ethylaminobutyrophenone).
- 153        96. Dimethylcathinone.
- 154        97. Dimethylmethcathinone.
- 155        98. Pentylone (3,4-Methylenedioxy-alpha-
- 156        methylaminovalerophenone).
- 157        99. MDPPP (3,4-Methylenedioxy-alpha-
- 158        pyrrolidinopropiophenone).
- 159        100. MDPBP (3,4-Methylenedioxy-alpha-
- 160        pyrrolidinobutyrophenone).
- 161        101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
- 162        102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
- 163        103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP  
(Benocyclidine).
- 165        104. F-MABP (Fluoromethylaminobutyrophenone).
- 166        105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
- 167        106. Et-PBP (Ethylpyrrolidinobutyrophenone).
- 168        107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
- 169        108. Me-EABP (Methylethylaminobutyrophenone).
- 170        109. Etizolam.
- 171        110. PPP (Pyrrolidinopropiophenone).
- 172        111. PBP (Pyrrolidinobutyrophenone).
- 173        112. PVP (Pyrrolidinovalerophenone) or  
(Pyrrolidinopentiophenone).

40-01109-17

20171618

- 175        113. MPPP (Methyl-alpha-pyrrolidinopropiophenone) .  
176        114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole) .  
177        115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole) .  
178        116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .  
179        117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole) .  
180        118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole) .  
181        119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole) .  
182        120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .  
183        121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-  
184        2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene) .  
185        122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole) .  
186        123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole) .  
187        124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) .  
188        125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole) .  
189        126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) .  
190        127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole) .  
191        128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole) .  
192        129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) .  
193        130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
194        (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
195        ol) .  
196        131. HU-308 ((1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan-  
197        2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]  
198        methanol) .  
199        132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-  
200        methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-  
201        1,4-dione) .  
202        133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene) .  
203        134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-

40-01109-17

20171618

204 undecanamide).

205 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-  
206 undecanamide).207 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-  
208 methyloctan-2-yl)phenol).

209 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

210 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).

211 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

212 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-  
213 methoxyphenylacetyl)indole).214 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-  
215 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-  
216 naphthalenylmethanone).217 142. WIN55,212-3 [(3S)-2,3-Dihydro-5-methyl-3-(4-  
218 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-  
219 naphthalenylmethanone).

220 143. Pentedrone (alpha-Methylaminovalerophenone).

221 144. Fluoroamphetamine.

222 145. Fluoromethamphetamine.

223 146. Methoxetamine.

224 147. Methiopropamine.

225 148. Methylbuphedrone (Methyl-alpha-  
226 methylaminobutyrophenone).

227 149. APB ((2-Aminopropyl)benzofuran).

228 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).

229 151. UR-144 (1-Pentyl-3-(2,2,3,3-  
230 tetramethylcyclopropanoyl)indole).231 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
232 tetramethylcyclopropanoyl)indole).

40-01109-17

20171618

- 233        153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
- 234        154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
- 235        155. AM-2233(1-[ (N-Methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole).
- 236        156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-carboxamide).
- 237        157. URB-597 ((3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-cyclohexylcarbamate).
- 238        158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester).
- 239        159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one).
- 240        160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 241        161. 2C-H (2,5-Dimethoxyphenethylamine).
- 242        162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 243        163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 244        164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-methoxybenzyl)phenethylamine].
- 245        165. MDMA (3,4-Methylenedioxymethamphetamine).
- 246        166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
- 247        167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-carboxylate).
- 248        168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-carboxylate).
- 249        169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-3-carboxamide).
- 250        170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide).

40-01109-17

20171618

- 262        171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
263 (4-fluorobenzyl)indazole-3-carboxamide).
- 264        172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-  
265 1-pentylindazole-3-carboxamide).
- 266        173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
267 yl)-1-(fluoropentyl)indole-3-carboxamide).
- 268        174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-  
269 methoxybenzyl)phenethylamine].
- 270        175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-  
271 methoxybenzyl)phenethylamine].
- 272        176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
273 (cyclohexylmethyl)indazole-3-carboxamide).
- 274        177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-  
275 carboxylate).
- 276        178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-  
277 3-carboxamide).
- 278        179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-  
279 (fluoropentyl)indazole-3-carboxamide).
- 280        180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
- 281        181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-  
282 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
- 283        182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-  
284 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-  
285 hexahydrobenzo[c]chromen-1-ol).
- 286        183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-  
287 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-  
288 hexahydrobenzo[c]chromen-1-ol).
- 289        184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-  
290 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9

40-01109-17

20171618

291 diol).

292       185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol).

295       186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).

297       187. MAPB ((2-Methylaminopropyl)benzofuran).

298       188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).

299       189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).

300       190. Synthetic Cannabinoids.—Unless specifically excepted or unless listed in another schedule or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation that contains any quantity of a synthetic cannabinoid found to be in any of the following chemical class descriptions, or homologues, nitrogen-heterocyclic analogs, isomers (including optical, positional, or geometric), esters, ethers, salts, and salts of homologues, nitrogen-heterocyclic analogs, isomers, esters, or ethers, whenever the existence of such homologues, nitrogen-heterocyclic analogs, isomers, esters, ethers, salts, and salts of isomers, esters, or ethers is possible within the specific chemical class or designation.

313       Since nomenclature of these synthetically produced cannabinoids is not internationally standardized and may continually evolve, these structures or the compounds of these structures shall be included under this subparagraph, regardless of their specific numerical designation of atomic positions covered, if it can be determined through a recognized method of scientific testing or analysis that the substance contains properties that fit within

40-01109-17

20171618

320 one or more of the following categories:

321       a. Tetrahydrocannabinols.—Any tetrahydrocannabinols  
322 naturally contained in a plant of the genus *Cannabis*, the  
323 synthetic equivalents of the substances contained in the plant  
324 or in the resinous extracts of the genus *Cannabis*, or synthetic  
325 substances, derivatives, and their isomers with similar chemical  
326 structure and pharmacological activity, including, but not  
327 limited to, Delta 9 tetrahydrocannabinols and their optical  
328 isomers, Delta 8 tetrahydrocannabinols and their optical  
329 isomers, Delta 6a,10a tetrahydrocannabinols and their optical  
330 isomers, or any compound containing a tetrahydrobenzo[c]chromene  
331 structure with substitution at either or both the 3-position or  
332 9-position, with or without substitution at the 1-position with  
333 hydroxyl or alkoxy groups, including, but not limited to:

334       (I) Tetrahydrocannabinol.

335       (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
336 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
337 ol).

338       (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
339 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-  
340 ol).

341       (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-  
342 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

343       (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-  
344 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

345       (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-  
346 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

347       (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3-  
348 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

40-01109-17

20171618

- 349                   (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-  
350                   6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).  
351                   (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-  
352                   6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).  
353                   (X) Parahexyl.  
354                   b. Naphthoylindoles, Naphthoylindazoles,  
355                   Naphthoylcarbazoles, Naphthylmethylindeoles,  
356                   Naphthylmethylindeazoles, and Naphthylmethylicarbazoles.—Any  
357                   compound containing a naphthoylindole, naphthoylindazole,  
358                   naphthoylcarbazole, naphthylmethylindeole,  
359                   naphthylmethylindeazole, or naphthylmethylicarbazole structure,  
360                   with or without substitution on the indole, indazole, or  
361                   carbazole ring to any extent, whether or not substituted on the  
362                   naphthyl ring to any extent, including, but not limited to:  
363                   (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).  
364                   (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-  
365                   naphthoyl)indole).  
366                   (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).  
367                   (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).  
368                   (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).  
369                   (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).  
370                   (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).  
371                   (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).  
372                   (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).  
373                   (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).  
374                   (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).  
375                   (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).  
376                   (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).  
377                   (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-

40-01109-17

20171618

378 naphthoyl) indole).  
379 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl) indole).  
380 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole).  
381 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-  
382 naphthoyl) indole).  
383 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl) indole).  
384 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl) indole).  
385 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl) indole).  
386 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl) indole).  
387 (XXII) JWH-184 (1-Pentyl-3-[ (4-methyl)-1-  
388 naphthylmethyl] indole).  
389 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1-  
390 naphthoyl) indole).  
391 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-  
392 naphthoyl) indole).  
393 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-  
394 naphthoyl) indole).  
395 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl) indole).  
396 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl) indole).  
397 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole).  
398 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl) indole).  
399 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl) indole).  
400 (XXXI) AM-1220 (1-[ (1-Methyl-2-piperidinyl)methyl]-3-(1-  
401 naphthoyl) indole).  
402 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-  
403 naphthoyl) indole).  
404 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-  
405 naphthoyl) indole).  
406 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-

40-01109-17

20171618

407 naphthoyl) indole).

408 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-  
409 naphthoyl) indole).

410 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl) indole).

411 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-  
412 naphthoyl) indazole).413 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-  
414 naphthoyl) indole).415 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-  
416 naphthoyl) indole).

417 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl) carbazole).

418 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-  
419 naphthoyl) carbazole).420 c. Naphthoylpyrroles.—Any compound containing a  
421 naphthoylpyrrole structure, with or without substitution on the  
422 pyrrole ring to any extent, whether or not substituted on the  
423 naphthyl ring to any extent, including, but not limited to:

424 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).

425 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).

426 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).

427 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).

428 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).

429 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-  
430 naphthoyl)pyrrole).431 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-  
432 naphthoyl)pyrrole).433 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-  
434 naphthoyl)pyrrole).

435 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-

40-01109-17

20171618

436 naphthoyl) pyrrole).

437 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-  
438 naphthoyl) pyrrole).

439 d. Naphthylmethylenindenes.—Any compound containing a  
440 naphthylmethylenindene structure, with or without substitution  
441 at the 3-position of the indene ring to any extent, whether or  
442 not substituted on the naphthyl ring to any extent, including,  
443 but not limited to, JWH-176 (3-Pentyl-1-  
444 (naphthylmethylene)indene).

445 e. Phenylacetylindoles and Phenylacetylindazoles.—Any  
446 compound containing a phenylacetylindole or phenylacetylindazole  
447 structure, with or without substitution on the indole or  
448 indazole ring to any extent, whether or not substituted on the  
449 phenyl ring to any extent, including, but not limited to:

450 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).  
451 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).  
452 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).  
453 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).  
454 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).  
455 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).  
456 (VII) Cannabipiperidiethanone.  
457 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-  
458 methoxyphenylacetyl)indole).

459 f. Cyclohexylphenols.—Any compound containing a  
460 cyclohexylphenol structure, with or without substitution at the  
461 5-position of the phenolic ring to any extent, whether or not  
462 substituted on the cyclohexyl ring to any extent, including, but  
463 not limited to:

464 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-

40-01109-17

20171618

465       yl)phenol).

466           (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)  
467 homologue).468           (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-  
469 methyloctan-2-yl)phenol).470           g. Benzoylindoles and Benzoylindazoles.—Any compound  
471 containing a benzoylindole or benzoylindazole structure, with or  
472 without substitution on the indole or indazole ring to any  
473 extent, whether or not substituted on the phenyl ring to any  
474 extent, including, but not limited to:

475           (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

476           (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

477           (III) AM-1241 (1-[ (N-Methyl-2-piperidinyl)methyl]-3-(2-  
478 iodo-5-nitrobenzoyl)indole).479           (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4-  
480 methoxybenzoyl)indole).481           (V) AM-2233 (1-[ (N-Methyl-2-piperidinyl)methyl]-3-(2-  
482 iodobenzoyl)indole).

483           (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

484           (VII) RCS-4 C4 homologue (1-Butyl-3-(4-  
485 methoxybenzoyl)indole).486           (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-ido-  
487 3-(4-methoxybenzoyl)indole).488           h. Tetramethylcyclopropanoylindoles and  
489 Tetramethylcyclopropanoylindazoles.—Any compound containing a  
490 tetramethylcyclopropanoylindole or  
491 tetramethylcyclopropanoylindazole structure, with or without  
492 substitution on the indole or indazole ring to any extent,  
493 whether or not substituted on the tetramethylcyclopropyl group

40-01109-17

20171618

494 to any extent, including, but not limited to:

495 (I) UR-144 (1-Pentyl-3-(2,2,3,3-

496 tetramethylcyclopropanoyl)indole).

497 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
498 tetramethylcyclopropanoyl)indole).

499 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-  
500 tetramethylcyclopropanoyl)indole).

501 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-  
502 tetramethylcyclopropanoyl)indole).

503 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-  
504 tetramethylcyclopropanoyl)indole).

505 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-  
506 tetramethylcyclopropanoyl)indole).

507 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-  
508 tetramethylcyclopropanoyl)indole).

509 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-  
510 tetramethylcyclopropanoyl)indazole).

511 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-  
512 tetramethylcyclopropanoyl)indole).

513 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-  
514 tetramethylcyclopropanoyl)indole).

515 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole  
516 carboxamides, and Adamantylindazole carboxamides.—Any compound  
517 containing an adamantoyl indole, adamantoyl indazole, adamantyl  
518 indole carboxamide, or adamantyl indazole carboxamide structure,  
519 with or without substitution on the indole or indazole ring to  
520 any extent, whether or not substituted on the adamantyl ring to  
521 any extent, including, but not limited to:

522 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).

40-01109-17

20171618

523                   (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-  
524 3-carboxamide).

525                   (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-  
526 carboxamide).

527                   (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-  
528 adamantoyl)indole).

529                   (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).

530                   (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).

531                   (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-  
532 adamantoyl)indole).

533                   j. Quinolinylindolecarboxylates,  
534 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,  
535 and Quinolinylindazolecarboxamides.—Any compound containing a  
536 quinolinylindole carboxylate, quinolinylindazole carboxylate,  
537 isoquinolinylindole carboxylate, isoquinolinylindazole  
538 carboxylate, quinolinylindole carboxamide, quinolinylindazole  
539 carboxamide, isoquinolinylindole carboxamide, or  
540 isoquinolinylindazole carboxamide structure, with or without  
541 substitution on the indole or indazole ring to any extent,  
542 whether or not substituted on the quinoline or isoquinoline ring  
543 to any extent, including, but not limited to:

544                   (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).

545                   (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-  
546 carboxylate).

547                   (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-  
548 carboxylate).

549                   (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-  
550 carboxylate).

551                   (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).

40-01109-17

20171618

552       (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole-  
553 3-carboxylate).

554       (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole-  
555 3-carboxylate).

556       (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).

557       (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3-  
558 carboxamide).

559       k. Naphthylindolecarboxylates and  
560 Naphthylindazolecarboxylates.—Any compound containing a  
561 naphthylindole carboxylate or naphthylindazole carboxylate  
562 structure, with or without substitution on the indole or  
563 indazole ring to any extent, whether or not substituted on the  
564 naphthyl ring to any extent, including, but not limited to:

565       (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-  
566 carboxylate).

567       (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-  
568 carboxylate).

569       (III) Fluoro SDB-005 (1-Naphthalenyl 1-  
570 (fluoropentyl)indazole-3-carboxylate).

571       (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-  
572 carboxylate).

573       (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-  
574 carboxylate).

575       l. Naphthylindole carboxamides and Naphthylindazole  
576 carboxamides.—Any compound containing a naphthylindole  
577 carboxamide or naphthylindazole carboxamide structure, with or  
578 without substitution on the indole or indazole ring to any  
579 extent, whether or not substituted on the naphthyl ring to any  
580 extent, including, but not limited to:

40-01109-17

20171618

- 581                   (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).  
582                   (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-  
583 3-carboxamide).  
584                   (III) Chloro-NNEI (N-Naphthalen-1-yl 1-  
585 (chloropentyl)indole-3-carboxamide).  
586                   (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-  
587 carboxamide).  
588                   (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-  
589 (fluoropentyl)indazole-3-carboxamide).  
590                   m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl  
591 indazole carboxamides, Alkylcarbonyl indole carboxylates, and  
592 Alkylcarbonyl indazole carboxylates.—Any compound containing an  
593 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,  
594 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-  
595 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an  
596 indole carboxamide, indazole carboxamide, indole carboxylate, or  
597 indazole carboxylate, with or without substitution on the indole  
598 or indazole ring to any extent, whether or not substituted on  
599 the alkylcarbonyl group to any extent, including, but not  
600 limited to:  
601                   (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
602 pentylinde-3-carboxamide).  
603                   (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
604 yl)-1-(fluoropentyl)indole-3-carboxamide).  
605                   (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
606 (fluoropentyl)indole-3-carboxamide).  
607                   (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
608 pentylinde-3-carboxamide).  
609                   (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-

40-01109-17

20171618

610 1-(fluoropentyl)indazole-3-carboxamide).  
611 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-  
612 1-pentylinidazole-3-carboxamide).  
613 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-  
614 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).  
615 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
616 (4-fluorobenzyl)indazole-3-carboxamide).  
617 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
618 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).  
619 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-  
620 (cyclohexylmethyl)indazole-3-carboxamide).  
621 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-  
622 (cyclohexylmethyl)indazole-3-carboxamide).  
623 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-  
624 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).  
625 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-  
626 pentylinidazole-3-carboxamide).  
627 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-  
628 (fluoropentyl)indazole-3-carboxamide).  
629 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-  
630 fluorobenzyl)indazole-3-carboxamide).  
631 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
632 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).  
633 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
634 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).  
635 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
636 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).  
637 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-  
638 fluoropentyl)indole-3-carboxamide).

40-01109-17

20171618

639                   (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-  
640 fluoropentyl)indazole-3-carboxamide).

641                   (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-  
642 (cyclohexylmethyl)indazole-3-carboxamide).

643                   (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-  
644 fluorobenzyl)indazole-3-carboxamide).

645                   (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-  
646 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).

647                   n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—  
648 Any compound containing a N-(2-phenylpropan-2-yl) indole  
649 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide  
650 structure, with or without substitution on the indole or  
651 indazole ring to any extent, whether or not substituted on the  
652 phenyl ring of the cumyl group to any extent, including, but not  
653 limited to:

654                   (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-  
655 carboxamide).

656                   (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-  
657 (fluoropentyl)indole-3-carboxamide).

658                   o. Other Synthetic Cannabinoids.—Any material, compound,  
659 mixture, or preparation that contains any quantity of a  
660 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

661                   (I) With or without modification or replacement of a  
662 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage  
663 between either two core rings, or linkage between a core ring  
664 and group structure, with or without the addition of a carbon or  
665 replacement of a carbon;

666                   (II) With or without replacement of a core ring or group  
667 structure, whether or not substituted on the ring or group

40-01109-17

20171618

668 structures to any extent; and

669       (III) Is a cannabinoid receptor agonist, unless  
670 specifically excepted or unless listed in another schedule or  
671 contained within a pharmaceutical product approved by the United  
672 States Food and Drug Administration.

673       191. Substituted Cathinones.—Unless specifically excepted,  
674 listed in another schedule, or contained within a pharmaceutical  
675 product approved by the United States Food and Drug  
676 Administration, any material, compound, mixture, or preparation,  
677 including its salts, isomers, esters, or ethers, and salts of  
678 isomers, esters, or ethers, whenever the existence of such salts  
679 is possible within any of the following specific chemical  
680 designations:

681           a. Any compound containing a 2-amino-1-phenyl-1-propanone  
682 structure;

683           b. Any compound containing a 2-amino-1-naphthyl-1-propanone  
684 structure; or

685           c. Any compound containing a 2-amino-1-thiophenyl-1-  
686 propanone structure,

687

688 whether or not the compound is further modified:

689       (I) With or without substitution on the ring system to any  
690 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,  
691 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused  
692 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide  
693 substituents;

694       (II) With or without substitution at the 3-propanone  
695 position with an alkyl substituent or removal of the methyl  
696 group at the 3-propanone position;

40-01109-17

20171618

697       (III) With or without substitution at the 2-amino nitrogen  
698 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or  
699 not further substituted in the ring system; or

700       (IV) With or without inclusion of the 2-amino nitrogen atom  
701 in a cyclic structure, including, but not limited to:

702       (A) Methcathinone.

703       (B) Ethcathinone.

704       (C) Methylone (3,4-Methylenedioxymethcathinone).

705       (D) 2,3-Methylenedioxymethcathinone.

706       (E) MDPV (3,4-Methylenedioxypyrovalerone).

707       (F) Methylmethcathinone.

708       (G) Methoxymethcathinone.

709       (H) Fluoromethcathinone.

710       (I) Methylethcathinone.

711       (J) Butylone (3,4-Methylenedioxy-alpha-methylaminobutyrophenone).

713       (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).

714       (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).

715       (M) Naphyrone (Naphthylpyrovalerone).

716       (N) Bromomethcathinone.

717       (O) Buphedrone (alpha-Methylaminobutyrophenone).

718       (P) Eutylone (3,4-Methylenedioxy-alpha-ethylaminobutyrophenone).

720       (Q) Dimethylcathinone.

721       (R) Dimethylmethcathinone.

722       (S) Pentylone (3,4-Methylenedioxy-alpha-methylaminovalerophenone).

724       (T) Pentedrone (alpha-Methylaminovalerophenone).

725       (U) MDPPP (3,4-Methylenedioxy-alpha-

40-01109-17

20171618

726 pyrrolidinopropiophenone).

727 (V) MDPBP (3,4-Methylenedioxy-alpha-  
728 pyrrolidinobutyrophenone).

729 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).

730 (X) PPP (Pyrrolidinopropiophenone).

731 (Y) PVP (Pyrrolidinovalerophenone) or  
732 (Pyrrolidinopentiophenone).

733 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).

734 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).

735 (BB) F-MABP (Fluoromethylaminobutyrophenone).

736 (CC) Me-EABP (Methylethylaminobutyrophenone).

737 (DD) PBP (Pyrrolidinobutyrophenone).

738 (EE) MeO-PBP (Methoxypyrrrolidinobutyrophenone).

739 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).

740 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).

741 (HH) Dimethylone (3,4-Methylenedioxy-N,N-  
742 dimethylcathinone).

743 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.

744 (JJ) 3,4-Methylenedioxy-N-acetylcatinone.

745 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.

746 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.

747 (MM) Methylbuphedrone (Methyl-alpha-  
748 methylaminobutyrophenone).

749 (NN) Methyl-alpha-methylaminohexanophenone.

750 (OO) N-Ethyl-N-methylcathinone.

751 (PP) PHP (Pyrrolidinohexanophenone).

752 (QQ) PV8 (Pyrrolidinoheptanophenone).

753 (RR) Chloromethcathinone.

754 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.

40-01109-17

20171618

755        192. Substituted Phenethylamines.—Unless specifically  
756        excepted or unless listed in another schedule, or contained  
757        within a pharmaceutical product approved by the United States  
758        Food and Drug Administration, any material, compound, mixture,  
759        or preparation, including its salts, isomers, esters, or ethers,  
760        and salts of isomers, esters, or ethers, whenever the existence  
761        of such salts is possible within any of the following specific  
762        chemical designations, any compound containing a phenethylamine  
763        structure, without a beta-keto group, and without a benzyl group  
764        attached to the amine group, whether or not the compound is  
765        further modified with or without substitution on the phenyl ring  
766        to any extent with alkyl, alkylthio, nitro, alkoxy, thio,  
767        halide, fused alkylenedioxy, fused furan, fused benzofuran,  
768        fused dihydrofuran, or fused tetrahydropyran substituents,  
769        whether or not further substituted on a ring to any extent, with  
770        or without substitution at the alpha or beta position by any  
771        alkyl substituent, with or without substitution at the nitrogen  
772        atom, and with or without inclusion of the 2-amino nitrogen atom  
773        in a cyclic structure, including, but not limited to:

- 774        a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
- 775        b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
- 776        c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
- 777        d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
- 778        e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
- 779        f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
- 780        g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
- 781        h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
- 782        i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 783        j. 2C-H (2,5-Dimethoxyphenethylamine).

40-01109-17

20171618

- 784           k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .  
785           l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .  
786           m. MDMA (3,4-Methylenedioxymethamphetamine) .  
787           n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-  
788 Methylenedioxy-N-methylbutanamine) .  
789           o. MDA (3,4-Methylenedioxymphetamine) .  
790           p. 2,5-Dimethoxyamphetamine.  
791           q. Fluoroamphetamine.  
792           r. Fluoromethamphetamine.  
793           s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine) .  
794           t. DOB (4-Bromo-2,5-dimethoxyamphetamine) .  
795           u. DOC (4-Chloro-2,5-dimethoxyamphetamine) .  
796           v. DOET (4-Ethyl-2,5-dimethoxyamphetamine) .  
797           w. DOI (4-Iodo-2,5-dimethoxyamphetamine) .  
798           x. DOM (4-Methyl-2,5-dimethoxyamphetamine) .  
799           y. PMA (4-Methoxyamphetamine) .  
800           z. N-Ethylamphetamine.  
801           aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.  
802           bb. 5-Methoxy-3,4-methylenedioxymphetamine.  
803           cc. PMMA (4-Methoxymethamphetamine) .  
804           dd. N,N-Dimethylamphetamine.  
805           ee. 3,4,5-Trimethoxyamphetamine.  
806           ff. 4-APB (4-(2-Aminopropyl)benzofuran) .  
807           gg. 5-APB (5-(2-Aminopropyl)benzofuran) .  
808           hh. 6-APB (6-(2-Aminopropyl)benzofuran) .  
809           ii. 7-APB (7-(2-Aminopropyl)benzofuran) .  
810           jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran) .  
811           kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran) .  
812           ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) .

40-01109-17

20171618

813 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).  
814 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).  
815 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).  
816 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).  
817 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).  
818 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).  
819 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-  
820 dihydrobenzofuran),

821  
822 which does not include phenethylamine, mescaline as described in  
823 subparagraph 20., substituted cathinones as described in  
824 subparagraph 191., N-Benzyl phenethylamine compounds as  
825 described in subparagraph 193., or methamphetamine as described  
826 in subparagraph (2)(c)4.

827 193. N-Benzyl Phenethylamine Compounds.—Unless specifically  
828 excepted or unless listed in another schedule, or contained  
829 within a pharmaceutical product approved by the United States  
830 Food and Drug Administration, any material, compound, mixture,  
831 or preparation, including its salts, isomers, esters, or ethers,  
832 and salts of isomers, esters, or ethers, whenever the existence  
833 of such salts is possible within any of the following specific  
834 chemical designations, any compound containing a phenethylamine  
835 structure without a beta-keto group, with substitution on the  
836 nitrogen atom of the amino group with a benzyl substituent, with  
837 or without substitution on the phenyl or benzyl ring to any  
838 extent with alkyl, alkoxy, thio, alkylthio, halide, fused  
839 alkylenedioxy, fused furan, fused benzofuran, or fused  
840 tetrahydropyran substituents, whether or not further substituted  
841 on a ring to any extent, with or without substitution at the

40-01109-17

20171618

842 alpha position by any alkyl substituent, including, but not  
843 limited to:

844 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-  
845 methoxybenzyl)phenethylamine].

846 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-  
847 hydroxybenzyl)phenethylamine].

848 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-  
849 fluorobenzyl)phenethylamine].

850 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-  
851 methylenedioxybenzyl)phenethylamine].

852 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-  
853 methoxybenzyl)phenethylamine].

854 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-  
855 hydroxybenzyl)phenethylamine].

856 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-  
857 fluorobenzyl)phenethylamine].

858 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-  
859 methylenedioxybenzyl)phenethylamine].

860 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-  
861 methoxybenzyl)phenethylamine].

862 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-  
863 methoxybenzyl)phenethylamine].

864 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-  
865 methoxybenzyl)phenethylamine].

866 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-  
867 methoxybenzyl)phenethylamine].

868 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-  
869 hydroxybenzyl)phenethylamine].

870 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-

40-01109-17

20171618

871 fluorobenzyl)]phenethylamine).

872       o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-methylenedioxybenzyl)]phenethylamine).

874       p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).

876       q. 25H-NBOH (2,5-Dimethoxy-[N-(2-hydroxybenzyl)]phenethylamine).

878       r. 25H-NBF (2,5-Dimethoxy-[N-(2-fluorobenzyl)]phenethylamine).

880       s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine),

882  
883 which does not include substituted cathinones as described in  
884 subparagraph 191.

885       194. Substituted Tryptamines.—Unless specifically excepted  
886 or unless listed in another schedule, or contained within a  
887 pharmaceutical product approved by the United States Food and  
888 Drug Administration, any material, compound, mixture, or  
889 preparation containing a 2-(1H-indol-3-yl)ethanamine, for  
890 example tryptamine, structure with or without mono- or di-  
891 substitution of the amine nitrogen with alkyl or alkenyl groups,  
892 or by inclusion of the amino nitrogen atom in a cyclic  
893 structure, whether or not substituted at the alpha position with  
894 an alkyl group, whether or not substituted on the indole ring to  
895 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy  
896 groups, including, but not limited to:

897       a. Alpha-Ethyltryptamine.

898       b. Bufotenine.

899       c. DET (Diethyltryptamine).

40-01109-17

20171618

900           d. DMT (Dimethyltryptamine) .  
901           e. MET (N-Methyl-N-ethyltryptamine) .  
902           f. DALT (N,N-Diallyltryptamine) .  
903           g. EiPT (N-Ethyl-N-isopropyltryptamine) .  
904           h. MiPT (N-Methyl-N-isopropyltryptamine) .  
905           i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine) .  
906           j. 5-Hydroxy-N-methyltryptamine.  
907           k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine) .  
908           l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine) .  
909           m. Methyltryptamine.  
910           n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) .  
911           o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine) .  
912           p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine) .  
913           q. DiPT (N,N-Diisopropyltryptamine) .  
914           r. DPT (N,N-Dipropyltryptamine) .  
915           s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine) .  
916           t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine) .  
917           u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine) .  
918           v. 4-AcO-DiPT (4-Acetoxy-N,N-Diisopropyltryptamine) .  
919           w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine) .  
920           x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine) .  
921           y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-  
922           isopropyltryptamine) .  
923           z. Methyl-alpha-ethyltryptamine.  
924           aa. Bromo-DALT (Bromo-N,N-diallyltryptamine) ,  
925  
926 which does not include tryptamine, psilocyn as described in  
927 subparagraph 34., or psilocybin as described in subparagraph 33.  
928         195. Substituted Phenylcyclohexylamines.—Unless

40-01109-17

20171618

929 specifically excepted or unless listed in another schedule, or  
930 contained within a pharmaceutical product approved by the United  
931 States Food and Drug Administration, any material, compound,  
932 mixture, or preparation containing a phenylcyclohexylamine  
933 structure, with or without any substitution on the phenyl ring,  
934 any substitution on the cyclohexyl ring, any replacement of the  
935 phenyl ring with a thiophenyl or benzothiophenyl ring, with or  
936 without substitution on the amine with alkyl, dialkyl, or alkoxy  
937 substituents, inclusion of the nitrogen in a cyclic structure,  
938 or any combination of the above, including, but not limited to:

- 939     a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP  
940 (Benocyclidine).
- 941     b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog  
942 of phencyclidine).
- 943     c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine  
944 analog of phencyclidine).
- 945     d. PCPr (Phenylcyclohexylpropylamine).
- 946     e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene  
947 analog of phencyclidine).
- 948     f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
- 949     g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
- 950     h. Methoxetamine.
- 951     i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
- 952     j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
- 953     k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
- 954     l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
- 955     m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
- 956     n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
- 957     o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).

40-01109-17

20171618

958 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).

959 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).

960 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).

961 196. CBD (Cannabidiol).

962 Section 2. This act shall take effect July 1, 2017.